In the article titled, "Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives" published in pages 22-31, issue 1, vol. 20 of Indian Journal of Endocrinology and Metabolism \[[@ref1]\], the references 30 and 31 in the reference list are written incorrectly.

The correct references are following:

Reference 30: Rosenstock J, Jelaska A, Frappin G, Salsali A, Kim G, Woerle HJ, *et al*. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care 2014;37:1815-23.

Reference 31: Rosenstock J, Jelaska A, Zeller C, Kim G, Broedl UC, Woerle HJ; EMPA-REG BASALTM Trial Investigators. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: A 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2015;17:936-48.

The references 30 and 31 cited in the article Tables 2 and 3 should be renumbered accordingly.
